Phylogica's CEO Dr Paul Watt said: We are delighted to be working with the IMB team at The University of Queensland because of their complementary expertise. Professor Kirill Alexandrov and Dr Yann Gambin are experts in the application of cutting edge microfluidics and fluorescence detection technologies, in combination with high-throughput and high-content protein characterisation. It is this technological synergy that led us to choose the IMB as our partner for the project. This world-class team has extensive experience of working with industry to achieve commercial objectives.
Heskumdai, reference here is to the team at IMB not Phylogica.. A couple of years in the Bio world on a project is nothing as we all know. This collaboration is what I'm most encouraged and excited about.
From Wayne;
Silence shouldn't be interpreted as lack of progress. Slide 35 of the April 2015 Investor Presentation points towards a commercial outcome in relation to Diagnostics (Universal Specificity). The spin-out/licensing opportunity appears to reference the collaboration with IMB, subject of the the initial ARC grant. The collaboration has just passed into its third and final year of grant funding. Of course slide 35 also points towards a commercial outcome in relation to Cyclops (macrocyclisation) which appears to reference the third ARC grant.
Tony
PYC Price at posting:
1.1¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)